• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clin Exp Nephrol . Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan

tetano

Editor, Senior Moderator
Clin Exp Nephrol


. 2022 Jun 3.
doi: 10.1007/s10157-022-02240-x. Online ahead of print.
Chronic kidney disease and clinical outcomes in patients with COVID-19 in Japan


Ryosuke Sato[SUP] 1 [/SUP], Yasushi Matsuzawa[SUP] 2 [/SUP], Hisao Ogawa[SUP] 3 [/SUP], Kazuo Kimura[SUP] 1 [/SUP], Nobuo Tsuboi[SUP] 4 [/SUP], Takashi Yokoo[SUP] 4 [/SUP], Hirokazu Okada[SUP] 5 [/SUP], Masaaki Konishi[SUP] 6 [/SUP], Jin Kirigaya[SUP] 7 [/SUP], Kazuki Fukui[SUP] 8 [/SUP], Kengo Tsukahara[SUP] 9 [/SUP], Hiroyuki Shimizu[SUP] 10 [/SUP], Keisuke Iwabuchi[SUP] 11 [/SUP], Yu Yamada[SUP] 12 [/SUP], Kenichiro Saka[SUP] 13 [/SUP], Ichiro Takeuchi[SUP] 7 [/SUP], Naoki Kashihara[SUP] 14 [/SUP], Kouichi Tamura[SUP] 6 [/SUP]



Affiliations

Abstract

Background: Identifying predictive factors for coronavirus disease 2019 (COVID-19) is crucial for risk stratification and intervention. Kidney dysfunction contributes to the severity of various infectious diseases. However, the association between on-admission kidney dysfunction and the clinical outcome in COVID-19 patients is unclear.
Methods: This study was a multicenter retrospective observational cohort study of COVID-19 patients, diagnosed by polymerase chain reaction. We retrospectively analyzed 500 COVID-19 patients (mean age: 51 ± 19 years) admitted to eight hospitals in Japan. Kidney dysfunction was defined as a reduced estimated glomerular filtration rate (< 60 mL/min/1.73 m[SUP]2[/SUP]) or proteinuria (≥ 1 + dipstick proteinuria) on admission. The primary composite outcome included in-hospital death, extracorporeal membrane oxygenation, mechanical ventilation (invasive and noninvasive methods), and intensive care unit (ICU) admission.
Results: Overall, 171 (34.2%) patients presented with on-admission kidney dysfunction, and the primary composite outcome was observed in 60 (12.0%) patients. Patients with kidney dysfunction showed higher rates of in-hospital death (12.3 vs. 1.2%), mechanical ventilation (13.5 vs. 4.0%), and ICU admission (18.1 vs. 5.2%) than those without it. Categorical and multivariate regression analyses revealed that kidney dysfunction was substantially associated with the primary composite outcome. Thus, on-admission kidney dysfunction was common in COVID-19 patients. Furthermore, it correlated significantly and positively with COVID-19 severity and mortality.
Conclusions: On-admission kidney dysfunction was associated with disease severity and poor short-term prognosis in patients with COVID-19. Thus, on-admission kidney dysfunction has the potential to stratify risks in COVID-19 patients.

Keywords: COVID-19; Clinical outcome; Kidney dysfunction.
 
Back
Top Bottom